Journal Article > Meta-AnalysisFull Text
Lancet Infect Dis. 2015 May 5; Volume 15 (Issue 7); DOI:10.1016/S1473-3099(15)00006-7
Rao VB, Johari N, du Cros PAK, Messina J, Ford NP, et al.
Lancet Infect Dis. 2015 May 5; Volume 15 (Issue 7); DOI:10.1016/S1473-3099(15)00006-7
An estimated 150 million people worldwide are infected with hepatitis C virus (HCV). HIV co-infection accelerates the progression of HCV and represents a major public health challenge. We aimed to determine the epidemiology of HCV and the prevalence of HIV co-infection in sub-Saharan Africa.
Journal Article > CommentaryFull Text
Public Health Action. 2014 September 21; Volume 4 (Issue 3); DOI:10.5588/pha.14.0028
Zachariah R, Kumar AMV, Reid A, Van der Bergh R, Isaakidis P, et al.
Public Health Action. 2014 September 21; Volume 4 (Issue 3); DOI:10.5588/pha.14.0028
Journal Article > CommentaryFull Text
Public Health Action. 2012 September 21; Volume 2 (Issue 3); DOI:10.5588/pha.12.0022
Bissell K, Harries AD, Reid A, Edginton ME, Hinderaker SG, et al.
Public Health Action. 2012 September 21; Volume 2 (Issue 3); DOI:10.5588/pha.12.0022
Journal Article > CommentaryFull Text
Trop Med Int Health. 2010 November 1; Volume 15 (Issue 11); DOI:10.1111/j.1365-3156.2010.02630.x
Zachariah R, Tayler-Smith K, Ngamvithayapong-Yana J, Ota M, Murakami K, et al.
Trop Med Int Health. 2010 November 1; Volume 15 (Issue 11); DOI:10.1111/j.1365-3156.2010.02630.x
Journal Article > CommentaryFull Text
Southern African Journal of HIV medicine. 2012 March 1
Andrieux-Meyer I, Clayden P, Collins S, Geffen N, Goemaere E, et al.
Southern African Journal of HIV medicine. 2012 March 1
Journal Article > CommentaryFull Text
BJOG. 2013 June 11; Volume 120 (Issue 8); DOI:10.1111/1471-0528.12131
Garry RF
BJOG. 2013 June 11; Volume 120 (Issue 8); DOI:10.1111/1471-0528.12131
Journal Article > LetterFull Text
Trop Med Int Health. 2013 May 30; Volume 18 (Issue 8); DOI:10.1111/tmi.12133
Zachariah R, Reid AJ, Van der Bergh R, Dahmane A, Kosgei RJ, et al.
Trop Med Int Health. 2013 May 30; Volume 18 (Issue 8); DOI:10.1111/tmi.12133
Journal Article > LetterFull Text
Lancet Global Health. 2014 August 19; Volume 2 (Issue 8); DOI:10.1016/S2214-109X(14)70252-9
Dorlo TPC, Balasegaram M
Lancet Global Health. 2014 August 19; Volume 2 (Issue 8); DOI:10.1016/S2214-109X(14)70252-9
Journal Article > CommentaryFull Text
Health Aff (Millwood). 2015 September 1; Volume 34 (Issue 9); 1569-1577.; DOI:10.1377/hlthaff.2015.0375
Kishore SP, Kolappa K, Jarvis JN, Park PH, Belt R, et al.
Health Aff (Millwood). 2015 September 1; Volume 34 (Issue 9); 1569-1577.; DOI:10.1377/hlthaff.2015.0375
The modern access-to-medicines movement grew largely out of the civil-society reaction to the HIV/AIDS pandemic three decades ago. While the movement was successful with regard to HIV/AIDS medications, the increasingly urgent challenge to address access to medicines for noncommunicable diseases has lagged behind-and, in some cases, has been forgotten. In this article we first ask what causes the access gap with respect to lifesaving essential noncommunicable disease medicines and then what can be done to close the gap. Using the example of the push for access to antiretrovirals for HIV/AIDS patients for comparison, we highlight the problems of inadequate global financing and procurement for noncommunicable disease medications, intellectual property barriers and concerns raised by the pharmaceutical industry, and challenges to building stronger civil-society organizations and a patient and humanitarian response from the bottom up to demand treatment. We provide targeted policy recommendations, specific to the public sector, the private sector, and civil society, with the goal of improving access to noncommunicable disease medications globally.
Journal Article > CommentaryFull Text
Trop Med Int Health. 2010 June 1; Volume 15; DOI:10.1111/j.1365-3156.2010.02506.x
Harries AD, Zachariah R, Lawn SD, Rosen S
Trop Med Int Health. 2010 June 1; Volume 15; DOI:10.1111/j.1365-3156.2010.02506.x
The scale-up of antiretroviral therapy (ART) has been one of the success stories of sub-Saharan Africa, where coverage has increased from about 2% in 2003 to more than 40% 5 years later. However, tempering this success is a growing concern about patient retention (the proportion of patients who are alive and remaining on ART in the health system). Based on the personal experience of the authors, 10 key interventions are presented and discussed that might help to improve patient retention. These are (1) the need for simple and standardized monitoring systems to track what is happening, (2) reliable ascertainment of true outcomes of patients lost to follow-up, (3) implementation of measures to reduce early mortality in patients both before and during ART, (4) ensuring uninterrupted drug supplies, (5) consideration of simple, non-toxic ART regimens, (6) decentralization of ART care to health centres and the community, (7) a reduction in indirect costs for patients particularly in relation to transport to and from clinics, (8) strengthening links within and between health services and the community, (9) the use of ART clinics to deliver other beneficial patient or family-orientated packages of care such as insecticide-treated bed nets, and (10) innovative (thinking 'out of the box') interventions. High levels of retention on ART are vital for individual patients, for credibility of programmes and for on-going resource and financial support.